Immatics Reports Interim Clinical Data from Ongoing Phase 1b Cohort A Monotherapy with ACTengine® IMA203 TCR-T Targeting PRAME
Update covers data from 11 heavily pre-treated, last-line patients in Phase 1b dose expansion Cohort A treated with IMA2…
Update covers data from 11 heavily pre-treated, last-line patients in Phase 1b dose expansion Cohort A treated with IMA2…
Interim clinical update on ACTengine® IMA203 TCR-T monotherapy targeting PRAME demonstrated high confirmed objective res…
Clinical validation of PRAME as multi-tumor target with large potential for TCR-based therapies: confirmed responses in…
Dose escalation for cell therapy candidate ACTengine® IMA203 ongoing; dose level 3 completed at doses below 1 billio…
Multi-target Adoptive Cell Therapy (ACT) with endogenous T cells against defined pHLA targets demonstrates feasibility…
EBT-Wachstum von 19 % auf 24,5 Millionen Euro (Q3-YTD-17/18: 20,5 Millionen Euro) (EBITDA-, EBIT- und EBT-Werte sind – s…
Revenues rise to 70.9 million euros, up 10 % (Q2-YTD-17/18: 64.7 million euros) EBT growth of 17 % to 14.9 million euros…
. Meyer Burger sichert wichtige strategische Partnerschaft...
. Meyer Burger enters into important strategic partnership with leading developer of highly efficient next generatio…
. - Umsatz bei 31,2 Millionen Euro, plus 10 % (Q1 16/17: 28,5 Millionen Euro) - EBT-Wachstum von 11 % auf 6,2 Millionen…